Skip to Content
Merck
  • Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.

Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.

Molecular and clinical oncology (2014-03-22)
Kwan Woo Kim, Hyuk-Chan Kwon, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Ji Hyun Lee, Myung Hwan Roh, Min Chan Kim, Ki Han Kim, Young Hoon Kim, Young Hoon Roh, Jin Sook Jeong, Hyo-Jin Kim
ABSTRACT

Biliary tract cancer (BTC) is a relatively uncommon type of cancer, accounting for ∼4% of the malignant neoplasms of the gastrointestinal tract. The aim of this study was to determine whether the expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) predict clinical outcome in BTC patients treated with adjuvant 5-fluorouracil (5-FU)-based chemotherapy. TS and TP expression were found to be significantly correlated with cancer location (P=0.044 and 0.031, respectively). The multivariate analysis revealed that age [hazard ratio (HR)=2.157, P=0.008], stage (HR=2.234, P<0.001), resection margin status (HR=2.748, P=0.004) and TP expression (HR=2.014, P=0.039) were independently associated with overall survival (OS).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Thymidylate Synthase Antibody, clone TS106, clone TS106, Chemicon®, from mouse